Treatment of advanced EGFR-mutated NSCLC patients relies on EGFR tyrosine kinase inhibitors (TKIs), which demonstrated superiority over chemotherapy as first-line therapy [2–5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.